Kazia Therapeutics Presents Paxalisib Data
Ticker: KZIA · Form: 6-K · Filed: Dec 10, 2025 · CIK: 1075880
Sentiment: neutral
Topics: clinical-trial-data, drug-development, oncology
TL;DR
Kazia Therapeutics dropped new data on paxalisib for brain cancer at AACR, looking promising.
AI Summary
On December 10, 2025, Kazia Therapeutics Limited issued a press release highlighting new clinical and translational findings for its drug candidate, paxalisib. The company presented data at the AACR Annual Meeting, showcasing positive results in glioblastoma and other cancers, with specific mention of a Phase 2 study in glioblastoma. The press release also touched upon ongoing research and development efforts for paxalisib.
Why It Matters
The presentation of positive clinical and translational data for paxalisib at a major scientific meeting could advance the drug's development and potential approval for cancer treatments.
Risk Assessment
Risk Level: medium — The company is in the clinical development phase, which carries inherent risks related to drug efficacy, safety, and regulatory approval.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- paxalisib (drug) — Drug candidate
- AACR Annual Meeting (event) — Scientific conference where data was presented
- glioblastoma (disease) — Cancer type being studied
- December 10, 2025 (date) — Date of press release
FAQ
What specific new clinical and translational findings were highlighted by Kazia Therapeutics?
The press release highlights new clinical and translational findings for paxalisib, with data presented at the AACR Annual Meeting, including positive results in glioblastoma and other cancers.
When was the press release issued by Kazia Therapeutics?
The press release was issued on December 10, 2025.
Where was the data for paxalisib presented?
The data for paxalisib was presented at the AACR Annual Meeting.
What is the primary indication being studied for paxalisib based on this filing?
The filing specifically mentions positive results in glioblastoma and ongoing research for other cancers, indicating glioblastoma as a primary focus.
What is the company's principal executive office address?
The company's principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Filing Stats: 270 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2025-12-10 16:11:42
Filing Documents
- d94168d6k.htm (6-K) — 9KB
- d94168dex991.htm (EX-99.1) — 23KB
- 0001193125-25-314196.txt ( ) — 33KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant's name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F INFORMATION CONTAINED IN THIS FORM 6-K REPORT On December 10, 2025, Kazia Therapeutics Limited (the "Company") issued a press release titled "Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+". A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend, Chief Executive Officer of the Company, and the quote of Professor Sudha Rao, Principal Investigator at QIMR Berghofer, contained in Exhibit 99.1, into the Company's registration statements on Form F-3 (File No. 333-281937). EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated December 10, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend Name: John Friend Title: Chief Executive Officer Date: December 10, 2025